Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

PURPOSE: To evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53(mut) or TP53(wt). PATIENTS AND METHODS: We analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally day...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollyea, Daniel A., Pratz, Keith W., Wei, Andrew H., Pullarkat, Vinod, Jonas, Brian A., Recher, Christian, Babu, Sunil, Schuh, Andre C., Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, DiNardo, Courtney D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751752/
https://www.ncbi.nlm.nih.gov/pubmed/36007102
http://dx.doi.org/10.1158/1078-0432.CCR-22-1183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751752/
https://www.ncbi.nlm.nih.gov/pubmed/36007102
http://dx.doi.org/10.1158/1078-0432.CCR-22-1183

Ejemplares similares